By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, banking on milestone payments from licensing and supply deals for its shots, ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $7 from $8 and keeps a Hold rating on the shares. The firm updated its model ahead of Q3 results to reflect recent industry data and ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 24.4% in the morning session after the company reported ...

Novavax NVAX shares soared 11.9% in the last trading session to close at $8.67. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Novavax (NASDAQ:NVAX) is gearing up to announce its quarterly earnings on Thursday, 2026-02-26. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

According to TipRanks.com, Hester is a 4-star analyst with an average return of 13.9% and a 50.0% success rate. Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) will be announcing earnings results tomorrow before market open. Here’s what you need to know. Novavax beat analysts’ revenue expectations last ...

Novavax (NVAX) delivered earnings and revenue surprises of +116.60% and +87.65%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?